A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco 5391959, California 5332921 and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- argenx
- ID
- NCT06742190
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 115 study participants
- Last Updated